Researchers at two California universities reviewed pivotal clinical trials done between 2017 and 2023. They found that only a small share of trials used to approve new drugs reflect the United States racial and ethnic makeup. Enrollment of Black and Hispanic people fell from 2021, while Asian participation rose and white participation stayed mainly steady.
The study notes many trials follow International Council for Harmonisation standards and take place in a few regions. It says much of Africa and large parts of Latin America are rarely included. The authors recommend setting diversity goals early, choosing testing locations to match local needs, and collecting biological samples to study drug responses.
Difficult words
- trial — a medical study to test a medicineclinical trials, trials
- enrollment — the act of people joining a study
- diversity — the presence of many different kinds of peoplediversity goals
- region — a large area of a country or worldregions
- sample — a small biological part taken for studybiological samples
- approve — to officially allow or accept something
Tip: hover, focus or tap highlighted words in the article to see quick definitions while you read or listen.
Discussion questions
- Why is it important for drug trials to include people from different racial and ethnic groups?
- What can researchers do to include people from Africa or Latin America?
- Would you join a clinical trial? Why or why not?
Related articles
New device measures blood viscosity in real time
Researchers at the University of Missouri created a non-invasive device that monitors blood viscosity and density in real time using ultrasound and software. It can read blood without drawing samples and may help in diseases like sickle cell.
Lower mGlu5 receptor found across autistic adult brains
A study in The American Journal of Psychiatry found lower availability of a glutamate receptor called mGlu5 across the brains of autistic adults. Researchers used PET, MRI and EEG and say the result could affect future diagnosis and treatment.
Personalized DNA vaccine shows promise against glioblastoma
A phase 1 trial found the personalized DNA vaccine GNOS-PV01 is safe and shows early signs of activity against glioblastoma. The small study at Siteman Cancer Center and WashU Medicine reported immune responses and encouraging clinical outcomes.